CipherBio PRO SVB Clients Discounts

CipherBio PRO SVB Clients Discounts

SVB Financial Group built and funded CipherBio to help Founders and CEOs raise capital. CipherBio PRO provides companies & VCs with access to $580B+ in global life science VC funding activity.

Most funding databases cost $5K to $15K per seat for an annual subscription. CipherBio is aware that Pre A companies cannot afford $5K+ per seat, so we built the best life science funding database and provided it to SVB Clients at a huge discount.

SVB Pre Series A clients pay $176 per seat annually for CipherBio PRO

SVB Post Series A clients pay $376 per seat annually for CipherBio PRO

SVB CorpVCs pay $376 per seat for CipherBio PRO (enter promo code SVBCORPVC)

SVB Client VCs pay $376 per seat for CipherBio PRO (enter promo code SVBCLIENTVC)

CipherBio Pricing

Right now, non-SVB clients pay $576 per seat annually for CipherBio PRO. Get an early discount now as prices will be increasing for non-clients soon.

CipherBio is the first life science market intelligence program that gives you interactive dashboards to drill down by indications, approaches and clinical stages in real-time to create the exact company and investor lists you need.

Sign up for CipherBio PRO today and download investor and company lists to Excel to help you raise capital or source deals.

Export to Excel

Access CipherBio PRO

Already using CipherBio PRO?

Thank you, and we want to hear about it. Tell us what you are finding interesting as you dig into the data.

Give us a call at
1-888-420-4752

 

You May Also Like

Most Active Corporate VCs in the Life Science Industry

Co-authored by Matt Gibbs CipherBio@svb and Steve Agular SVB Managing Director, VC…
MicroBiome Insights

64 Microbiome Biotechs Raise $1.6 Billion in Investments

In the last decade, a relatively uncharted field exploded in the life…
Cell Therapy Insights

$18 Billion Invested in 135 Cell Therapy Companies

Cell therapy was born in the 1930s when Paul Niehans earned the…
CipherBio 2020 Biotech Industry Report

2020 Biotech Funding Overview

It has been an unprecedented year so far for Biotech industry and…